Of particular significance is the potential for eosinophils and FeNO to serve as biomarkers of IL-5, IL-4Ra, or TSLP-driven inflammation, as these cytokines may constitute targets for future biological therapies, regardless of the co-existence of asthma or COPD. Here, IL5 is linked to asthma.